Letter to the Editor
Nephron 1995;70:123-124
Ravindra Mittala
Sanjiv Saxena*
Sandeep Guleriab
S.K. Mittala
S.K. Agarwala
S.C. Tiwaria
S.C. Dasha
Departments of
a Nephrology and
b Surgery, AIIMS, New Delhi, India
Visceral Leishmaniasis: A Rare
Cause of Unexplained Pyrexia in
a Renal Allograft Recipient
Dear Sir,
Visceral leishmaniasis or kala-azar has
not been recognised as a common infection
in renal allograft recipients. However, im
munodeficiency states can facilitate the reac
tivation of a dormant illness in infected pa
tients or predispose such patients to infec
tion in endemic areas. Indeed, following its
first description in renal transplant recipi
ents in 1979 [1], in recent years more case
reports have described such an association
[2-5]. In contrast to the non-immunodefi-
cient patients, the disease is often more ful
minant and poorly responsive to therapy in
these high risk patients [3]. We report here a
case of visceral leishmaniasis in a renal allo
graft recipient who presented with pyrexia of
undetermined origin and showed an excel
lent response to pentavalent antimonials.
A 23-ycar-old young male, resident of
Bihar, India, underwent a one-haplotype-
matched live related renal transplantation
for Alport’s syndrome with end stage renal
disease at our centre in December 1992.
Immunosuppression given comprised three
drugs - azathioprine, prednisolone and cy
closporine, with a gradual tapering off from
cyclosporine from 3 months onwards so as to
be completely weaned off by 9 months. The
early posttransplant period was uneventful.
In June 1993 the patient was admitted
for evaluation of his pyrexia of unknown ori
gin of 3 weeks duration. The fever was high
grade and remittent in nature without any
localising symptoms. He had received an
empirical course of antimalarials twice
(chloroquine followed by a sulphamethoxa-
zole and pyrimethamine combination) and
also broad-spectrum antibiotics (ampicillin
and norfloxacin) for his pyrexia in Bihar
without response. Physical examination re
vealed a pale, anicteric, febrile patient with
no significant peripheral lymphadenopathy.
He was normotensivc and the cardiovascu
lar and respiratroy systems were normal. Ab
dominal examination showed a 2-cm hepa
tomegaly and a firm 3-cm splenomegaly with
the allograft being normal and non-tender.
Investigations on admission revealed a
haemoglobin of 6.4 g/dl, reticulocyte count
1%, total leucocyte count 3,200/mm3, plate
let count of 90.000/mm3 and ESR of 33 mm
in the 1st h. Blood urea was 30 mg/dl. serum
creatinine 1 mg/dl, scrum bilirubin 0.9 mg/
dl. SGOT 86 IU/ml, SGPT 93 lU/ml and an
alkaline phosphatase of 86 IU/ml. The total
proteins were 7.1 g/dl with the serum albu
min being 3.2 g/dl and the globulins 3.9 g/dl.
The rest of serum biochemistry was normal.
A routine urinalysis and 24-hour urine ex
amination were normal. Radiography of the
chest was normal. Peripheral smears for ma
larial parasites were negative on three occa
sions and repeated blood, urine and throat
cultures were sterile. Widal test was negative
and showed no increase in titre serially. Se
rology for cytomegalovirus was negative for
both IgM and IgG antibodies. Mantoux test
was negative. Abdominal ultrasonography
showed hepatosplenomegaly but no retro
peritoneal lymph nodes or masses. The pa
tient was initially treated with ciprofloxacin
500 mg b.d. for 2 weeks without response. A
repeat empirical course of antimalarials was
also administered without success. In view
of leucopenia. the patient was restarted on
cyclosporine at a dose of 2 mg/kg/day and
azathioprine was discontinued.
A bone marrow examination was done
subsequently and the smears were full of
amastigote forms of Leishmania donovcini.
Definitive therapy was then instituted in the
form of sodium antimony gluconate started
in a dose of 8 mg/kg/day in view of deranged
LFTs and then stepped up to a dose of 15
mg/kg/day. The patient showed an excellent
response with amelioration of toxemia and
became afebrile after 7 days of therapy. The
therapy was, however, continued for a total
of 2 weeks. A repeat bone marrow examina
tion done after 4 weeks was reported nega
tive for Leishman-Donovan bodies. The pa
tient was discharged with normal counts,
normal renal parameters and normal LFTs
at completion of therapy. The patient has
been under follow-up for the last 6 months
without recurrence of the disease.
Visceral leishmaniasis or kala-azar is en
demic in several parts of India with 30 of the
39 districts of Bihar having been identified
as currently endemic areas by the WHO [6].
To the best of our knowledge, only 12 cases,
including this report, of visceral leishmania
sis in renal allograft recipients have been
described so far [2-5]. Four of these patients
(33.3%) had a fatal outcome mainly due to
supcrinfection, most often Pseudomonas
septicemia, or disseminated intravascular
coagulation [2, 3], and only 8 patients
(66.6%) have survived after antiprotozoal
therapy [4, 5], The outcome depends on ear
ly diagnosis and treatment - which may be
delayed because this diagnosis is often not
considered in the first place and secondly
because of a misleading presentation of the
disease in such immunocompromised hosts.
The optimum dosage and duration of treat-
Dr. Sanjiv Saxcna, Assist. Prof.
Department of Nephrology
AIIMS
New Delhi (India)
© 1995 S. Karger AG, Basel
0028-2766/95/0701-0123
$ 8. 00/0